Belimumab reduces antiphospholipid antibodies in primary triple-positive antiphospholipid syndrome

Autoimmun Rev. 2020 Aug;19(8):102594. doi: 10.1016/j.autrev.2020.102594. Epub 2020 Jun 12.

Authors

Philipp Klemm¹, Ulf Müller-Ladner², Ingo H Tarner², Uwe Lange², Ole Hudowenz²

Affiliations

¹ Campus Kerckhoff of Justus Liebig University Giessen, Dept. of Rheumatology, Immunology, Osteology and Physical Medicine, Germany. Electronic address: p.klemm@kerckhoff-klinik.de.
² Campus Kerckhoff of Justus Liebig University Giessen, Dept. of Rheumatology, Immunology, Osteology and Physical Medicine, Germany.

PMID: 32535091
DOI: 10.1016/j.autrev.2020.102594

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antibodies, Antiphospholipid / blood
Antibodies, Antiphospholipid / immunology*
Antibodies, Monoclonal, Humanized / therapeutic use*
Antiphospholipid Syndrome / blood
Antiphospholipid Syndrome / drug therapy*
Antiphospholipid Syndrome / immunology*
Female
Humans

Substances

Antibodies, Antiphospholipid
Antibodies, Monoclonal, Humanized
belimumab